Clinical Study on Tongluo Pingchuan Decoction in the Treatment of Infantile Cough Variant Asthma
10.16466/j.issn1005-5509.2024.05.013
- VernacularTitle:通络平喘方治疗儿童咳嗽变异性哮喘的临床应用研究
- Author:
Fei LIU
1
;
Yu WANG
;
Wei PAN
Author Information
1. 无锡市中医医院 江苏,无锡 214000
- Keywords:
Tongluo Pingchuan Decoction;
cough variant asthma;
inflammatory factors;
airway hyperresponsiveness;
dissolve phlegm,dispel stasis,and unblock collaterals;
therapeutic effect;
mechanism
- From:
Journal of Zhejiang Chinese Medical University
2024;48(5):590-596
- CountryChina
- Language:Chinese
-
Abstract:
[Objective]To investigate the clinical efficacy and possible mechanism of Tongluo Pingchuan Decoction in the treatment of infantile cough variant asthma(CVA).[Methods]Seventy-two patients with CVA were randomized into treatment group(36 cases)and control group(36 cases).Treatment group were treated with Tongluo Pingchuan Decoction while the cases in control group were treated with oral Ambroxol and Montelukast.Then the mitigation of cough symptoms and the changes of immunoglobulin E(IgE),eosinophils(EOS),interleukin-4(IL-4)and interferon-γ(IFN-γ)were observed.[Results]After treatment,the symptom scores were both decreased(P<0.01),and the treatment group was superior to the control group(P<0.01,P<0.05).The efficacy of the treatment group was better than that of the control group(P<0.05),and the onset time of the treatment group was significantly shorter than that of the control group(P<0.05).The level of EOS,IgE,IL-4 and IFN-γ of two groups were improved after treatment(P<0.01),and there was no statistically difference between the two groups(P>0.05).After 3 months of follow-up,the recurrence rate of the two groups was statistically different(P<0.01).[Conclusion]Tongluo Pingchuan Decoction can significantly relieve the cough symptoms of in children with CVA,reduce the recurrence rate,and the possible mechanism may be associated with regulating inflammatory factor levels.
